Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 1/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.45 |
| ▸ | KDM1A | O60341 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.40 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | TRPV3 | Q8NET8 | 6/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1034606 | 0.91 | KDM1A (0.48) | SCN9AMAP4K4KDM1ACTSSPIM1 | |
| SCHEMBL13627227 | 0.82 | CTSS (0.47) | KDM1AALDH1A1CTSSTRPV3 | |
| SCHEMBL1034161 | 0.78 | CTSS (0.47) | KDM1AALDH1A1CTSSTRPV3 | |
| SCHEMBL1032552 | 0.78 | CTSS (0.47) | KDM1AALDH1A1CTSSTRPV3 | |
| SCHEMBL1035236 | 0.77 | MAPT (0.50) | MAP4K4KDM1AALDH1A1ITGB3ITGA2B | |
| SCHEMBL1031605 | 0.76 | RXFP1 (0.48) | MAP4K4KDM1ACTSSPIM1 | |
| SCHEMBL13854087 | 0.75 | CTSS (0.58) | KDM1AALDH1A1CTSS | |
| SCHEMBL1035339 | 0.74 | KIF11 (0.47) | ALDH1A1TRPV3PIM1 | |
| SCHEMBL1033262 | 0.74 | SCN9A (0.48) | SCN9AALDH1A1CTSSTRPV3 | |
| SCHEMBL1032856 | 0.71 | KDM1A (0.50) | KDM1AALDH1A1CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102083438-B | The quinoline of conditioning agent and related analogs as silent message regulatory factor | 西特里斯药业公司 | 2016-11-09 | — | — | CN | disclosed |
| CN-102083438-A | Quenolines and related analogs as sirtuin modulators | SIRTRIS PHARMACEUTICALS INC | 2011-06-01 | — | — | CN | disclosed |
| US-20110046110-A1 | QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2011-02-24 | — | — | US | disclosed |
| US-20110046110-A1 | QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2011-02-24 | — | — | US | disclosed |
| US-20110046110-A1 | QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2011-02-24 | — | — | US | disclosed |
| EP-2273992-A1 | QUENOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS | Sirtris Pharmaceuticals, Inc. (US) | 2011-01-19 | — | — | EP | disclosed |
| WO-2009134973-A1 | QUENOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2009-11-05 | — | — | WO | disclosed |
| WO-2009134973-A1 | QUENOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2009-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046110-A1 | QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRT3, SIRT1, SIRT2 | SCN9A 3526/4885MAP4K4 1524/4885KDM1A 1199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.